Intensive Education on Lipid Management

NCT ID: NCT01925079

Last Updated: 2013-08-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 2568 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2015-06-30

Brief Summary

Among the patients with coronary heart disease, those with ACS (acute coronary syndrome) are extremely high-risk patients. Therefore, management outside hospital, especially the regular administration of drugs, is vital to prevent the recurrence of cardiovascular events. However, most patients often fail to stay on a long-term administration regimen, especially the administration of statins. According to the statistics, the average duration adhered with statin in patients with ACS is less than 3 months, use of statin at hospital discharge was only 80% and 65% in 6 month, with a very low LDL-C control rate (about 11% at 6 months), which poses a threat to the recurrence rate of cardiovascular events in patients with ACS.

It was found in previous studies that there were many factors influencing patients' compliance, in which patients' refusing to take medicine accounted for a higher proportion. It suggests that patient had not recognized the importance of long-term administration. Therefore, it is extremely important for physicians to strengthen patient education and regular follow-up visits during disease management. Moreover, the effectiveness of patient education during chronic disease management has already been proved in some studies abroad, and the interventional effect of multiple patient education process outweighs that of single approach education.

Thus, we intend to conduct a randomized and controlled study to explore the effect of multi-channel intensive patient education on LDL-C target achieving rate and statin adherence in patients with ACS in China.

Conditions

Acute Coronary Syndrome

Keywords

acute coronary syndrome; statins; LDL-C; intensive education

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intensive Educational Group

The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.

Group Type: EXPERIMENTAL

Intensive Education

Intervention Type: BEHAVIORAL

Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.

Patient education:

1. Routine education at discharge.

2. 4 education brochures will be delivered to patients.

3. Calendar with healthy tips will be delivered to patients before discharge.

4. A follow-up brochure with medical expert letter.

5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).

6. Telephone follow ups will be performed according to a standard communication document.

At discharge, patients will be given a brochure for future follow up.

Control Group

The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.

Group Type: SHAM_COMPARATOR

Control

Intervention Type: OTHER

Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.

Patient education:

1. Routine education at discharge.

2. A follow-up brochure without medical expert letter.

At discharge, patients will be given a brochure for future follow up.

Interventions

Intensive Education

Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.

Patient education:

1. Routine education at discharge.

2. 4 education brochures will be delivered to patients.

3. Calendar with healthy tips will be delivered to patients before discharge.

4. A follow-up brochure with medical expert letter.

5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).

6. Telephone follow ups will be performed according to a standard communication document.

At discharge, patients will be given a brochure for future follow up.

Intervention Type: BEHAVIORAL

Control

Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.

Patient education:

1. Routine education at discharge.

2. A follow-up brochure without medical expert letter.

At discharge, patients will be given a brochure for future follow up.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. The patients admitted to the hospital with a diagnosis of ACS including those for first consulting or with recurrence. The patient was prescribed atorvastatin (Lipitor®) by physicians in hospital;

2. The age of patient enrolled will be ≥18 years old;

3. The patient is able to understand and complete questionnaire.

4. The patients agree to accept follow-up visits, and willing to participate in patient education courses and sign informed consent form.

Exclusion Criteria

1. The patient has contraindications to statins, such as active hepatic disease, patient has a history of intolerance or hypersensitivity to statins or has a history of prior rhabdomyolysis on a statin.

2. The patient who uses other statins except Lipitor® when discharged from the hospital;

3. Cardiac function class of the patient is class IV(NYHA);

4. The patient has a malignant tumor;

5. The patient has a severe arrhythmia.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fujian Medical University

OTHER

Sponsor Role: collaborator

The Second Affiliated Hospital of Harbin Medical University

OTHER

Sponsor Role: collaborator

Xi'an Jiaotong University

OTHER

Sponsor Role: collaborator

The Luhe Teaching Hospital of the Capital Medical University

OTHER

Sponsor Role: collaborator

Junbo Ge

OTHER

Sponsor Role: lead

Responsible Party

Junbo Ge

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Junbo Ge, Professor

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

The 2nd affiliated hospital of harbin medical university

Harbin, Heilongjiang, China

Xi'an Jiaotong University College of Medicine

Xi’an, Shanxi, China

The Luhe Teaching Hospital of the Capital Medical University

Beijing, , China

Shanghai Zhongshan Hospital

Shanghai, , China

Countries

China

Central Contacts

Bingqing Huang

Role: CONTACT

Phone: 86-13816586495

Email: huang.bingqing@zs-hospital.sh.cn

Other Identifiers

ACS-lipid-2013

Identifier Type: -

Identifier Source: org_study_id